Basel (dpa-AfX)-The Swiss pharmaceutical company Roche stops the administration of gene therapy Elevidys for the treatment of Duchenne Muskeldystrophy (DMD) in non-capable patients. The step takes place after two deaths due to acute liver failure.
The benefit-risk ratio of Elevidys in non-capable DMD patients was re-evaluated after a clinical review, said Roche on Sunday. The company is deeply affected by the death of the two young men and is working on reducing risks associated with Elevidys treatment.
In the clinical area, the administration of the therapy to non-capable patients is now being paused immediately, in the commercial area it will be completely hired, said Roche. The administration of elevidys to walk-in DMD patients of all ages is not affected: the benefit-risk ratio remains positive for this.
DMD is a rare, progressive muscle disease that is accompanied by increasing muscle loss and especially affects male patients. The disease begins in childhood and progresses quickly. The ability to go, as well as the functions of the upper limbs, the lungs and the heart. The disease occurs in about one of 5,000 newly born boys ./tp/awp/he
Selected leverage products on Roche
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Roche
The lever must be between 2 and 20
Advertising